Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis
| Autor: | Anja Windhagen, Jan Klatt, Elke Wiesemann, Fedor Heidenreich, C. Wenzel |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty Multiple Sclerosis medicine.medical_treatment Immunology Enzyme-Linked Immunosorbent Assay Adjuvants Immunologic Internal medicine Clinical Studies medicine Humans Immunology and Allergy Lymphocytes Glatiramer acetate Interleukin 5 Analysis of Variance Interleukin-13 business.industry Multiple sclerosis Glatiramer Acetate Middle Aged medicine.disease In vitro Treatment Outcome Cytokine Endocrinology Mechanism of action Interleukin 13 Disease Progression Female Analysis of variance Interleukin-5 medicine.symptom Peptides business medicine.drug |
| Zdroj: | Clinical and Experimental Immunology. 133:454-460 |
| ISSN: | 1365-2249 0009-9104 |
| DOI: | 10.1046/j.1365-2249.2003.02238.x |
| Popis: | SUMMARY Glatiramer acetate (GA) is effective in the treatment of Multiple Sclerosis (MS) presumably by the induction of an immunoregulatory T-cell response. We have previously shown that GA directly induces the Th2 cytokines IL-13 and IL-5 in T-cells in vitro. In the present study we compared the in vitro response to GA in healthy controls, untreated and GA-treated MS patients and tested whether the induction of IL-13 and IL-5 secretion is also detectable in the serum of 25 MS patients treated with GA. Patients were grouped into clinical responders and nonresponders in order to determine a possible correlation with the immunological response. As a result we found a significant increase of IL-13 in the serum of clinical GA-responders whereas IL-13 was not detectable in controls, untreated MS (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|